Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Draft Guidance From US FDA Discusses Trials For Novel Diabetes Treatments

Executive Summary

The document discusses feasibility studies on devices that use therapies like neurostimulation or changes to the small intestine to better control blood glucose levels in people with type 2 diabetes.

You may also be interested in...



Fractyl Adds $100M Investment To Address Root Causes Of Type 2 Diabetes

The series F financing will allow the company to expand clinical research supporting its unique duodenal mucosal resurfacing approach to treating metabolic disease at its source.

AdvaMed’s MedTech ’21: Focus On MCIT, MDUFA At Hybrid Meeting

Virtual and in-person events are planned for Washington, DC, and Minneapolis, MN, during the trade group gathering.

Medtronic Beats Back Axonics’ Challenge To InterStim Patents

The US patent office has upheld all seven patents at issue, with the verdict on the final three having come on 22 September.

Topics

UsernamePublicRestriction

Register

MT143957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel